## Ioav Z Cabantchik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1743315/publications.pdf

Version: 2024-02-01

1040056 1058476 14 764 9 14 citations h-index g-index papers 14 14 14 1081 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Pathophysiology of Iron Overloada. Annals of the New York Academy of Sciences, 1998, 850, 191-201.	3.8	217
2	NEET Proteins: A New Link Between Iron Metabolism, Reactive Oxygen Species, and Cancer. Antioxidants and Redox Signaling, 2019, 30, 1083-1095.	5.4	129
3	Structure–function analysis of NEET proteins uncovers their role as key regulators of iron and ROS homeostasis in health and disease. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 1294-1315.	4.1	128
4	Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease. BMC Neurology, 2015, 15, 74.	1.8	83
5	Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood, 2022, 139, 3018-3029.	1.4	50
6	Clinical Experience With Deferiprone Treatment for Friedreich Ataxia. Journal of Child Neurology, 2016, 31, 1036-1040.	1.4	45
7	Protein bioavailability of Wolffia globosa duckweed, a novel aquatic plant – A randomized controlled trial. Clinical Nutrition, 2019, 38, 2576-2582.	5.0	41
8	Vaccine efficacy and iron deficiency: an intertwined pair?. Lancet Haematology, the, 2021, 8, e666-e669.	4.6	28
9	The mechanism of interaction between high-affinity probes and the uridine transport system of mammalian cells. Journal of Cellular Physiology, 1976, 89, 831-838.	4.1	23
10	A Combined Drug Treatment That Reduces Mitochondrial Iron and Reactive Oxygen Levels Recovers Insulin Secretion in NAF-1-Deficient Pancreatic Cells. Antioxidants, 2021, 10, 1160.	5.1	7
11	The [2Feâ€2S] protein CISD2 plays a key role in preventing iron accumulation in cardiomyocytes. FEBS Letters, 2022, 596, 747-761.	2.8	6
12	Hepcidin Expression in Cultured Liver Cells Responds Differently to Iron Overloaded Sera Derived from Patients with Thalassemia and Hemochromatosis Blood, 2004, 104, 3196-3196.	1.4	3
13	<scp>Plasma nontransferrin bound ironâ€"</scp> nontransferrin bound iron <scp>revisited:</scp> Implications for systemic iron overload and in iv iron supplementation. American Journal of Hematology, 2022, 97, 7-9.	4.1	3
14	Labile plasma iron as an indicator of patient adherence to iron chelation treatment. Blood Cells, Molecules, and Diseases, 2018, 71, 1-4.	1.4	1